Skip to main content
. 2022 Nov 29;10(2):608–617. doi: 10.1016/j.gendis.2022.10.023

Figure 5.

Fig. 5

Antibody responses to inactivated COVID-19 vaccines in central obesity and noncentral obesity. (A, B) The seropositivity rate and antibody titers of anti-RBD-IgG (A) and NAbs (B) in central obesity and noncentral obesity individuals. (C, D) The seropositivity rate and antibody titers of anti-RBD-IgG (C) and NAbs (D) in central obesity and noncentral obesity individuals at 1 month, 2 months, and 3 months. The error bars in antibody titers indicate the 95%CI of the GMTs. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. CI, confidential interval; anti-RBD-IgG, spike receptor-binding domain IgG antibody; NAbs, neutralizing antibodies.